Parathyroid Disorders Market Research Report- Forecast to 2027

Parathyroid Disorders Market Size, Application And Trends Analysis By Type (Hyperparathyroidism, Parathyroid Cancer, Hypoparathyroidism), Diagnosis (Blood Test, Imaging, Urine Test), Treatment (Surgery, Radiation Therapy, Drugs), End User -Forecast Till 2027

ID: MRFR/Pharma/4005-HCR | February 2021 | Region: Global | 85 pages

Parathyroid Disorders Market Scenario:


Parathyroid glands produce and secrete a parathyroid hormone which is involved in regulation of calcium and phosphorus metabolism. Hyperparathyroidism and Hypoparathyroidism are the two most common parathyroid disorders. The hyperparathyroidism is characterized by an excessive secretion of parathyroid hormone. The most common signs and symptoms of the disorder include kidney stones, bone and joint pain, fragile bones, weakness.


According to a study published in the Turkish Journal of Trauma and Emergency Surgery in 2016, it is found that hyperparathyroidism is the third most common clinical endocrine disorder with a prevalence between 0.1–1.0%, and an incidence of around 28 cases per 100,000 individuals. It also reported that the incidence rate is highest between 50 and above age group i.e. the condition is affecting 2% of the population aged 55 years or older.


Notably, rising prevalence of parathyroid disorders and growing geriatric population are the key factors driving the parathyroid disorders market.


Various other factors such as increasing incidences of parathyroid disorders, increasing government assistance, rising healthcare expenditures, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the parathyroid disorders market. According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014 i.e. EUR 321 billion, which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion.


Despite these drivers, there are some issues associated with parathyroid disorders market. Some of the challenges include less research and development funding, side-effects of treatment, the presence of misbranded and spurious drugs, expiration of patented drugs and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.


It is estimated that the parathyroid disorders market is expected to grow at a CAGR 6.5% during the forecast period of 2017-2023.


Research Methodology:


 Parathyroid disorders


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience:



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Medical Device Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


Segmentation


The parathyroid disorders market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of the type, the parathyroid disorders market is classified as hyperparathyroidism (HPT), parathyroid cancer, and hypoparathyroidism. The hyperparathyroidism is further segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism.


On the basis of the diagnosis, the parathyroid disorders market is classified as blood tests, imaging tests, and urine tests. The imaging tests is further sub-segmented into CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, X-ray, ultrasound, bone density test, and sestamibi scan.


On the basis of the treatment, the parathyroid disorders market is classified as surgery, radiation therapy, drugs, and others. The drugs segment is further sub-segmented into calcimimetics, hormone replacement therapy, and bisphosphonates.


On the basis of the end-user, the parathyroid disorders market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.


Regional Analysis:


The Americas dominate the parathyroid disorders market owing to the rising prevalence of parathyroid disorders and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.


Europe holds the second position in the parathyroid disorders market. It is expected that the support provided by the government bodies for research & development and improvement in the reimbursement policies in the healthcare is likely to drive the market of the European region.


The Asia Pacific region is the fastest growing parathyroid disorders market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.


The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.


Key Players


Some of the key players in the parathyroid disorders market are Abbott Laboratories, Alcon Laboratories, Inc., Amgen Inc., Bayer Healthcare, Becton, Dickinson and Company, Eli Lilly, Ethicon, Inc., Genentech, Medtronic, Merck, Mylan Laboratories, Novartis, Novo Nordisk, Pfizer, Roche, Smith & Nephew plc, Stryker, Teva Pharmaceutical Industries Ltd., Zimmer Biomet Holdings, Inc., and others.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.5% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories, Alcon Laboratories, Inc., Amgen Inc., Bayer Healthcare, Becton, Dickinson and Company, Eli Lilly, Ethicon, Inc., Genentech, Medtronic, Merck, Mylan Laboratories, Novartis, Novo Nordisk, Pfizer, Roche, Smith & Nephew plc, Stryker, Teva Pharmaceutical Industries Ltd., Zimmer Biomet Holdings, Inc., and others
  Key Market Opportunities

  • Increasing incidences of parathyroid disorders
  • Increasing government assistance
  • Rising healthcare expenditures
  • Improving regulatory framework
  • Rising funding and reimbursement policies
  •   Key Market Drivers

  • Rising prevalence of parathyroid disorders
  • Growing geriatric population


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The the parathyroid disorder market obstacles are lack of funding, poor healthcare system in under-developed regions, side-effects, anomalies in drug market, and others.

    parathyroid disorder market CAGR would be 6.5% during the forecast period.

    By treatment, the parathyroid disorder market segments are surgery, radiation therapy, drugs, and others.

    The Americas would dominate the parathyroid disorder market.

    The parathyroid disorder market segments based on diagnosis are blood test, imaging test, and urine test.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Parathyroid Disorders Market, by Type

    6.1 Introduction

    6.2 Simple Parathyroid Disorders

    6.2.1 Market Estimates & Forecast, 2020 – 2027

    6.3 Complex Parathyroid Disorders

    6.3.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 7. Global Parathyroid Disorders Market, by Diagnosis

    7.1 Introduction

    7.2 Physical Examination

    7.2.1 Market Estimates & Forecast, 2020 – 2027

    7.3 Laboratory Tests

    7.3.1 Market Estimates & Forecast, 2020 – 2027

    7.4 Electroencephalogram (EEG)

    7.4.1 Market Estimates & Forecast, 2020 – 2027

    7.5 Others

    7.5.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 8. Global Parathyroid Disorders Market, by treatment

    8.1 Introduction

    8.2 Home Management

    8.2.1 Market Estimates & Forecast, 2020 – 2027

    8.3 Antipyretic Medication

    8.3.1 Market Estimates & Forecast, 2020 – 2027

    8.4 Others

    8.4.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 9. Global Parathyroid Disorders Market, by Distribution Channel

    9.1 Introduction

    9.2 Hospitals

    9.2.1 Market Estimates & Forecast, 2020 – 2027

    9.3 Clinics

    9.3.1 Market Estimates & Forecast, 2020 – 2027

    9.4 Diagnostic Centers

    9.4.1 Market Estimates & Forecast, 2020 – 2027

    9.5 Drug Stores

    9.5.1 Market Estimates & Forecast, 2020 – 2027

    9.6 Pharmacies

    9.6.1 Market Estimates & Forecast, 2020 – 2027

    9.7 Others

    9.7.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 10. Global Parathyroid Disorders Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 Abbott Laboratories

    12.1.1 Company Overview

    12.1.2 Types Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Alcon Laboratories, Inc.

    12.2.1 Company Overview

    12.2.2 Types Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Amgen Inc.

    12.3.1 Company Overview

    12.3.2 Types Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Bayer Healthcare

    12.4.1 Company Overview

    12.4.2 Types/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Becton, Dickinson and Company

    12.5.1 Company Overview

    12.5.2 Types Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 Eli Lilly

    12.6.1 Company Overview

    12.6.2 Types Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Ethicon, Inc.

    12.7.1 Overview

    12.7.2 Types Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Others

    Chapter 12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Parathyroid Disorders industry

    Chapter 13 Appendix

    LIST OF TABLES

    Table 1 Parathyroid Disorders Industry Synopsis, 2020 – 2027

    Table 2 Parathyroid Disorders Market Estimates and Forecast, 2020 – 2027, (USD Million)

    Table 3 Parathyroid Disorders Market by Region, 2020 – 2027, (USD Million)

    Table 4 Parathyroid Disorders Market by Type, 2020 – 2027, (USD Million)

    Table 5 Parathyroid Disorders Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 6 Parathyroid Disorders Market by Treatment, 2020 – 2027, (USD Million)

    Table 7 Parathyroid Disorders Market by End User, 2020 – 2027, (USD Million)

    Table 8 North America Parathyroid Disorders Market by Type, 2020 – 2027, (USD Million)

    Table 9 North America Parathyroid Disorders Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 10 North America Parathyroid Disorders Market by Treatment, 2020 – 2027, (USD Million)

    Table 11 North America Parathyroid Disorders Market by End User, 2020 – 2027, (USD Million)

    Table 12 US Parathyroid Disorders Market by Type, 2020 – 2027, (USD Million)

    Table 13 US Parathyroid Disorders Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 14 US Parathyroid Disorders Market by Treatment, 2020 – 2027, (USD Million)

    Table 15 US Parathyroid Disorders Market by End User, 2020 – 2027, (USD Million)

    Table 16 Canada Parathyroid Disorders Market by Type, 2020 – 2027, (USD Million)

    Table 17 Canada Parathyroid Disorders market by Diagnosis, 2020 – 2027, (USD Million)

    Table 18 Canada Parathyroid Disorders Market by Treatment, 2020 – 2027, (USD Million)

    Table 19 Canada Parathyroid Disorders market by End User, 2020 – 2027, (USD Million)

    Table 20 South America Parathyroid Disorders Market by Type, 2020 – 2027, (USD Million)

    Table 21 South America Parathyroid Disorders Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 22 South America Parathyroid Disorders Market by Treatment, 2020 – 2027, (USD Million)

    Table 23 South America Parathyroid Disorders Market by End User, 2020 – 2027, (USD Million)

    Table 24 Europe Parathyroid Disorders Market by Type, 2020 – 2027, (USD Million)

    Table 25 Europe Parathyroid Disorders Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 26 Europe Parathyroid Disorders Market by Treatment, 2020 – 2027, (USD Million)

    Table 27 Europe Parathyroid Disorders Market by End User, 2020 – 2027, (USD Million)

    Table 28 Western Europe Parathyroid Disorders Market by Type, 2020 – 2027, (USD Million)

    Table 29 Western Europe Parathyroid Disorders Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 30 Western Europe Parathyroid Disorders Market by Treatment, 2020 – 2027, (USD Million)

    Table 31 Western Europe Parathyroid Disorders Market by End User, 2020 – 2027, (USD Million)

    Table 32 Eastern Europe Parathyroid Disorders Market by Type, 2020 – 2027, (USD Million)

    Table 33 Eastern Europe Parathyroid Disorders market by Diagnosis, 2020 – 2027, (USD Million)

    Table 34 Eastern Europe Parathyroid Disorders Market by Treatment, 2020 – 2027, (USD Million)

    Table 35 Eastern Europe Parathyroid Disorders Market by End User, 2020 – 2027, (USD Million)

    Table 36 Asia Pacific Parathyroid Disorders Market by Type, 2020 – 2027, (USD Million)

    Table 37 Asia Pacific Parathyroid Disorders Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 38 Asia Pacific Parathyroid Disorders Market by Treatment, 2020 – 2027, (USD Million)

    Table 39 Asia Pacific Parathyroid Disorders market by End User, 2020 – 2027, (USD Million)

    Table 40 Middle East & Africa Parathyroid Disorders Market by Type, 2020 – 2027, (USD Million)

    Table 41 Middle East & Africa Parathyroid Disorders Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 42 Middle East & Africa Parathyroid Disorders Market by Treatment, 2020 – 2027, (USD Million)

    Table 43 Middle East & Africa Parathyroid Disorders market by End User, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Parathyroid Disorders Market

    Figure 3 Segmentation Market Dynamics for Parathyroid Disorders Market

    Figure 4 Global Parathyroid Disorders market Share, by Type 2020

    Figure 5 Global Parathyroid Disorders market Share, by Diagnosis 2020

    Figure 6 Global Parathyroid Disorders market Share, by Treatment 2020

    Figure 7 Global Parathyroid Disorders market Share, by End User, 2020

    Figure 8 Global Parathyroid Disorders market Share, by Region, 2020

    Figure 9 North America Parathyroid Disorders market Share, by Country, 2020

    Figure 10 Europe Parathyroid Disorders market Share, by Country, 2020

    Figure 11 Asia Pacific Parathyroid Disorders market Share, by Country, 2020

    Figure 12 Middle East & Africa Parathyroid Disorders market Share, by Country, 2020

    Figure 13 Global Parathyroid Disorders market: Company Share Analysis, 2020 (%)

    Figure 14 Abbott Laboratories: Key Financials

    Figure 15 Abbott Laboratories Segmental Revenue

    Figure 16 Abbott Laboratories: Geographical Revenue

    Figure 17 Alcon Laboratories, Inc.: Key Financials

    Figure 18 Alcon Laboratories, Inc.: Segmental Revenue

    Figure 19 Alcon Laboratories, Inc.: Geographical Revenue

    Figure 20 Amgen Inc.: Key Financials

    Figure 21 Amgen Inc.: Segmental Revenue

    Figure 22 Amgen Inc.: Geographical Revenue

    Figure 23 Bayer Healthcare: Key Financials

    Figure 24 Bayer Healthcare: Segmental Revenue

    Figure 25 Bayer Healthcare: Geographical Revenue

    Figure 26 Becton, Dickinson and Company: Key Financials

    Figure 27 Becton, Dickinson and Company: Segmental Revenue

    Figure 28 Becton, Dickinson and Company Geographical Revenue

    Figure 29 Eli Lilly: Key Financials

    Figure 30 Eli Lilly: Segmental Revenue

    Figure 31 Eli Lilly: Geographical Revenue

    Figure 32 Ethicon, Inc.: Key Financials

    Figure 33 Ethicon, Inc.: Segmental Revenue

    Figure 34 Ethicon, Inc.: Geographical Revenue